SpringWorks Therapeutics Trading Volume Surges to 207th Position Amid Acquisition News

On June 18, 2025, SpringWorks Therapeutics (SWTX) saw a significant increase in trading volume, with a total turnover of $365 million, marking an 86.18% rise from the previous day. This surge placed the company at the 207th position in terms of trading volume for the day. However, the stock price experienced a slight decline of 0.15%, marking the second consecutive day of decrease, with a total drop of 0.17% over the past two days.

Germany-based pharmaceutical company Merck KGaA has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics (SWTX) for approximately $3.9 billion. This acquisition is expected to significantly impact the market dynamics for SpringWorks, potentially leading to increased investor interest and market activity.

Reports indicate that shares of SpringWorks Therapeutics reached a session high on Thursday, driven by news that Germany's Merck KGaA is nearing a deal to acquire the company. This development has sparked speculation among investors about the potential benefits and challenges that may arise from the acquisition, contributing to the stock's recent volatility.